2,389 Shares in Boston Scientific Co. (NYSE:BSX) Purchased by D Orazio & Associates Inc.

D Orazio & Associates Inc. acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,389 shares of the medical equipment provider’s stock, valued at approximately $241,000.

Several other hedge funds also recently bought and sold shares of the stock. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. Union Bancaire Privee UBP SA purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $33,074,000. Van ECK Associates Corp increased its position in Boston Scientific by 1.9% during the fourth quarter. Van ECK Associates Corp now owns 58,984 shares of the medical equipment provider’s stock worth $5,268,000 after purchasing an additional 1,090 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock worth $6,529,000 after purchasing an additional 21,173 shares during the period. Finally, Everhart Financial Group Inc. raised its stake in Boston Scientific by 6.6% during the fourth quarter. Everhart Financial Group Inc. now owns 15,108 shares of the medical equipment provider’s stock worth $1,349,000 after purchasing an additional 932 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on BSX shares. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. Truist Financial upped their price target on Boston Scientific from $113.00 to $117.00 and gave the stock a “buy” rating in a research note on Thursday, April 24th. Royal Bank of Canada lifted their price objective on Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Needham & Company LLC reissued a “buy” rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Finally, Barclays lifted their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Twenty-one analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $116.00.

Boston Scientific Trading Up 1.1%

NYSE:BSX opened at $99.60 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market cap of $147.35 billion, a PE ratio of 79.68, a P/E/G ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17. The business’s 50 day moving average is $101.03 and its two-hundred day moving average is $98.79.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.56 EPS. On average, analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer now directly owns 1,476,882 shares of the company’s stock, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the transaction, the executive vice president now owns 178,342 shares of the company’s stock, valued at $18,347,824.96. This trade represents a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 411,970 shares of company stock worth $42,406,693. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.